Przejdź do zawartości
Merck

A novel truncated form of S100P predicts disease-free survival in patients with lymph node positive breast cancer.

Cancer letters (2015-08-16)
Liping Chung, Leo Phillips, Mike Z Lin, Katrina Moore, Deborah J Marsh, Frances M Boyle, Robert C Baxter
ABSTRAKT

The calcium-binding protein S100P is overexpressed in various cancers and may contribute to the oncogenic phenotype. This study used mass spectrometry to characterize a novel 9.2-kDa C-terminally truncated form of S100P (t-S100P), and to investigate its potential prognostic value in breast cancer. Univariate analysis demonstrated the association between breast tissue t-S100P levels (n = 148) and conventional pathological markers. Across all tumor samples, high t-S100P was strongly prognostic for poor disease-free survival (P = 0.005), its efficacy confined to lymph node-positive tumors (n = 74, P = 0.007). Matrix-assisted laser desorption/ionization imaging mass spectrometry confirmed differential t-S100P abundance between breast cancer and unaffected adjacent tissue. t-S100P was exclusively located in the cell nucleus of breast cancer tissue, and full-length S100P was essentially undetectable by mass spectrometry. We conclude that t-S100P is the predominant form of S100P in breast cancer tissue and is strongly prognostic for disease-free survival in women with lymph node-positive disease.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
Acetonitrile, anhydrous, 99.8%
Sigma-Aldrich
Acetonitrile, electronic grade, 99.999% trace metals basis
Sigma-Aldrich
3,3′-Diaminobenzidine, 97%
Sigma-Aldrich
3,3′-Diaminobenzidine, 97% (HPLC)
Sigma-Aldrich
Hematoxylin
Sigma-Aldrich
Hematoxylin, certified by the BSC